AU2001276737A1 - Protein injection preparations - Google Patents
Protein injection preparationsInfo
- Publication number
- AU2001276737A1 AU2001276737A1 AU2001276737A AU7673701A AU2001276737A1 AU 2001276737 A1 AU2001276737 A1 AU 2001276737A1 AU 2001276737 A AU2001276737 A AU 2001276737A AU 7673701 A AU7673701 A AU 7673701A AU 2001276737 A1 AU2001276737 A1 AU 2001276737A1
- Authority
- AU
- Australia
- Prior art keywords
- injection preparations
- protein injection
- protein
- preparations
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000237432 | 2000-08-04 | ||
| JP2000-237432 | 2000-08-04 | ||
| PCT/JP2001/006739 WO2002011753A1 (en) | 2000-08-04 | 2001-08-06 | Protein injection preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001276737A1 true AU2001276737A1 (en) | 2002-02-18 |
Family
ID=18729296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001276737A Abandoned AU2001276737A1 (en) | 2000-08-04 | 2001-08-06 | Protein injection preparations |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040038878A1 (en) |
| EP (1) | EP1336410A4 (en) |
| JP (1) | JP5490972B2 (en) |
| AU (1) | AU2001276737A1 (en) |
| WO (1) | WO2002011753A1 (en) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1259547E (en) * | 2000-03-01 | 2012-10-15 | Medimmune Inc | High potency recombinant antibodies and method for producing them |
| HU230874B1 (en) * | 2000-05-15 | 2018-11-29 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical compositions stable at room temperature which comprising a pegylated human erythropoietin protein |
| US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| WO2006050166A2 (en) * | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methods of preventing and treating rsv infections and related conditions |
| CA2600608A1 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising human igg2 antibody and chelating agent |
| JP5053264B2 (en) * | 2005-05-19 | 2012-10-17 | アムジェン インコーポレイテッド | Compositions and methods for increasing antibody stability |
| CN101217979A (en) | 2005-06-14 | 2008-07-09 | 安姆根有限公司 | Self-buffering protein formulations |
| JP5553506B2 (en) * | 2006-03-22 | 2014-07-16 | 中外製薬株式会社 | Erythropoietin solution formulation |
| AU2007307107B2 (en) * | 2006-10-06 | 2011-11-03 | Amgen Inc. | Stable antibody formulations |
| MX2009003982A (en) * | 2006-10-20 | 2009-04-27 | Amgen Inc | Stable polypeptide formulations. |
| CA2681752A1 (en) | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Crystalline anti-human 1l-12 antibodies |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| CA2696594C (en) | 2007-08-27 | 2019-03-19 | Biogenerix Ag | Liquid formulation of g-csf conjugate |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| CN104645329A (en) * | 2007-11-30 | 2015-05-27 | Abbvie公司 | Protein formulations and methods of making same |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| EP2328607A1 (en) | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
| HRP20130414T1 (en) | 2008-10-21 | 2013-06-30 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| CN102202682B (en) | 2008-11-04 | 2015-08-19 | Aska制药株式会社 | Containing the waterborne compositions of follicle stimulating hormone |
| JP2012510468A (en) * | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | Stable antibody composition and method for stabilizing the same |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| CA2760185A1 (en) * | 2009-05-04 | 2010-11-11 | Abbott Biotechnology Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha antibodies |
| CA2726232A1 (en) * | 2009-07-16 | 2010-08-12 | Arecor Limited | Stable formulation of a therapeutic protein |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| RS61082B1 (en) | 2010-02-26 | 2020-12-31 | Novo Nordisk As | Stable antibody containing compositions |
| CA2791685C (en) | 2010-03-01 | 2019-07-23 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| RU2012153786A (en) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | STABLE MULTI-DOSE COMPOSITIONS CONTAINING ANTIBODY AND CONSERVANT |
| BR112013011699B1 (en) | 2010-11-11 | 2019-04-24 | Abbvie Biotechnology Ltd | LIQUID WATER FORMULATIONS, PRE-FILLED SYRINGE OR SELF-INJECTOR DEVICE AND USE OF THESE FORMULATIONS TO TREAT A DISORDER ASSOCIATED WITH THE COMMITTED TNF ACTIVITY |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| US20140017318A1 (en) * | 2012-07-10 | 2014-01-16 | Kevin O'Connell | Method to produce a medicinal product comprising a biologically active protein and the resulting product |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| CA2883272A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
| EP3701968A1 (en) | 2012-09-07 | 2020-09-02 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
| HK1207960A1 (en) | 2013-03-12 | 2016-02-19 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
| US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| AR097762A1 (en) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | DRY FORMULATIONS OF VACCINES THAT ARE STABLE AT ENVIRONMENTAL TEMPERATURE |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| WO2015075201A1 (en) | 2013-11-21 | 2015-05-28 | Genmab A/S | Antibody-drug conjugate lyophilised formulation |
| TW201609145A (en) * | 2013-12-25 | 2016-03-16 | 參天製藥股份有限公司 | Injectable agent and depot formation method |
| AR099470A1 (en) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | LIQUID CORRAL BIRD VIRUS VACCINES |
| TWI670085B (en) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | Swine virus vaccines that are liquid stable |
| AR103173A1 (en) | 2014-12-22 | 2017-04-19 | Novarits Ag | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US12115227B2 (en) | 2016-01-13 | 2024-10-15 | Genmab A/S | Formulation for antibody and drug conjugate thereof |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| SG11201903521XA (en) | 2016-10-21 | 2019-05-30 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| JP2020534366A (en) | 2017-09-20 | 2020-11-26 | アルヴォテック エイチエフ | Pharmaceutical formulation for adalimumab |
| TWI841554B (en) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate |
| WO2019217455A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| TWI844571B (en) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate |
| CN120324338A (en) * | 2025-06-10 | 2025-07-18 | 厦门特宝生物工程股份有限公司 | A liquid preparation for injection of recombinant human granulocyte macrophage stimulating factor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5920647B2 (en) * | 1976-10-01 | 1984-05-15 | 武田薬品工業株式会社 | injection |
| JP2648301B2 (en) | 1983-12-27 | 1997-08-27 | ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド | Vector containing auxiliary DNA for transformation of eukaryotic cells |
| JPS6197229A (en) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | Stable erythropoietin preparation |
| US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
| US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| AU646822B2 (en) | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
| GB9001987D0 (en) * | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
| JPH0565233A (en) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | Monoclonal antibody-containing lyophilized preparation |
| JPH0710753A (en) * | 1993-06-25 | 1995-01-13 | Taisho Pharmaceut Co Ltd | Injection |
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| PT814841E (en) * | 1995-03-21 | 2002-03-28 | Applied Research Systems | HCG LIQUID FORMULATIONS |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| JPH08333277A (en) * | 1995-06-05 | 1996-12-17 | Hoechst Japan Ltd | Human blood coagulation factor XIII stabilized aqueous liquid preparation |
| JPH09241178A (en) * | 1996-03-07 | 1997-09-16 | Takeda Chem Ind Ltd | Method for producing sustained-release preparation of corticotropin derivative |
| TW518219B (en) * | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| JP3723857B2 (en) * | 1998-02-04 | 2005-12-07 | 日本ケミカルリサーチ株式会社 | Aqueous pharmaceutical composition containing human growth hormone |
| EP1952820A3 (en) * | 1998-03-06 | 2012-06-20 | Chugai Seiyaku Kabushiki Kaisha | Protein-free G-CSF formulations |
-
2001
- 2001-08-06 EP EP01954460A patent/EP1336410A4/en not_active Withdrawn
- 2001-08-06 AU AU2001276737A patent/AU2001276737A1/en not_active Abandoned
- 2001-08-06 JP JP2002517088A patent/JP5490972B2/en not_active Expired - Fee Related
- 2001-08-06 US US10/343,487 patent/US20040038878A1/en not_active Abandoned
- 2001-08-06 WO PCT/JP2001/006739 patent/WO2002011753A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002011753A1 (en) | 2002-02-14 |
| JP5490972B2 (en) | 2014-05-14 |
| EP1336410A1 (en) | 2003-08-20 |
| EP1336410A4 (en) | 2005-10-12 |
| US20040038878A1 (en) | 2004-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001276737A1 (en) | Protein injection preparations | |
| AU2001232799A1 (en) | Protein c derivatives | |
| AU2001236005A1 (en) | Preparations stabilized over long time | |
| AU2001294192A1 (en) | Solid preparations | |
| AU2001277781A1 (en) | Stabilized antibody-containing preparations | |
| AU2001273164A1 (en) | Membrane associated protein zupari | |
| AU2001282607A1 (en) | Solution preparations stabilized over long time | |
| AU2001242479A1 (en) | Proliposomal encapsulated preparations | |
| AU2001286721A1 (en) | Human interleukin-four induced protein | |
| AU2001259450A1 (en) | Cytoskeleton-associated proteins | |
| AU2001288102A1 (en) | Solid preparations | |
| AU2001282521A1 (en) | OCT preparations | |
| AU2001272427A1 (en) | Solid preparations | |
| AU2001244863A1 (en) | Apoptin-associating protein | |
| AU2002239747A1 (en) | Cystoskeleton-associated proteins | |
| AU2001250585A1 (en) | Insecticidal peptides and methods for using same | |
| AU3506800A (en) | Leukocyte- and blood-associated proteins | |
| AU2002243234A1 (en) | Embryogenesis associated proteins | |
| AU1540701A (en) | Novel protein | |
| AU2001278777A1 (en) | Irap-binding protein | |
| AU2001278975A1 (en) | Alpha-conotoxin peptides | |
| AU2002240889A1 (en) | Proteins that interact with betatrcp | |
| AU2002500A (en) | Novel protein | |
| AU2001284748A1 (en) | Reaper protein | |
| AU2001241044A1 (en) | Mitf-associated proteins |